A neurological sleep disorder causing excessive daytime sleepiness not explained by other conditions.
✦ AI summary
Idiopathic hypersomnia (IH) is grouped with narcolepsy under "central disorders of hypersomnolence," conditions that are chronic, rare, and disabling, marked by excessive daytime sleepiness that significantly affects quality of life [4][8]. Research shows people with IH often carry a heavy burden of other health issues, including cardiovascular, cardiometabolic, and kidney-related conditions, along with higher rates of back pain, headache/migraine, and depression [2][8]. In fact, depression appears especially common in IH, with one study finding nearly 64% of IH patients had significant depressive symptoms, the highest among the hypersomnolence disorders studied [9]. Even with treatment, many people with IH continue to experience residual sleepiness and reduced quality of life, pointing to gaps in how well current treatments work [4][8]. On the medication side, low-sodium oxybate is noted as an FDA-approved treatment for IH in adults, and researchers are also exploring drugs that target the orexin system as potential future therapies [5][7][11]. Some sleep medicine training surveys note that doctors-in-training generally get adequate exposure to IH during fellowship, though gaps remain in managing
This is an AI-generated summary of the sources below — not medical advice. Always talk to a doctor or pharmacist about your own situation.
Nocturnal sleep-related scratching disorder as a possible variant of NREM arousal disorder: Clinical features and polysomnographic study of four newly reported cases.
A clinical variant of NREM arousal disorder is described manifesting with predominantly injurious, and exclusively sleep-related scratching without any conscious awareness, and without a history of dermatologic disease. Four patients were clinically evaluated and underwent videopolysomnography (vPSG…
The Italian registry for narcolepsy and central disorders of hypersomnolence (ReN&IS): Baseline clinical and diagnostic findings.
Central disorders of hypersomnolence, a wide and heterogeneous group of neurological disorders including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), are chronic, rare, under-recognized, and disabling conditions characterized by excessive daytime sleepiness (EDS…
Sodium-relevant comorbidity risk factors are highly prevalent in individuals with narcolepsy or idiopathic hypersomnia.
Individuals with narcolepsy or idiopathic hypersomnia (IH) present with a high comorbidity burden that may confer elevated risk for negative clinical outcomes associated with excess sodium intake. This study characterized the prevalence and profiles of sodium-relevant comorbidity risk factors among…
Assessment of readiness in the diagnosis and management of central disorders of hypersomnolence: A survey of sleep medicine program directors and fellowship graduates.
Central disorders of hypersomnolence (CDH), including narcolepsy, idiopathic hypersomnia, and recurrent hypersomnia, are rare conditions that pose challenges in sleep medicine fellowship training. Limited exposure to these disorders, variability in training experiences, and growing complexity of dia…
Comparison of heart rate responses at respiratory event termination in children referred for assessment of hypersomnolence.
Adult studies have linked disorders of hypersomnolence to impaired heart rate (HR) control. We examined HR changes during obstructive and central respiratory events in children referred for assessment of hypersomnolence compared to controls. 20 children diagnosed with narcolepsy, 7 with idiopathic h…
The purpose of this article is to provide an overview of how to evaluate, diagnose, and manage patients with hypersomnia disorders. The extended-release formulation of sodium oxybate to treat narcolepsy with a dosage of once a night, rather than twice a night, was approved in 2023 for adults and in…
Burden among participants with central disorders of hypersomnolence in six European countries.
Narcolepsy types 1 and 2 (NT1/NT2) and idiopathic hypersomnia (IH) are central disorders of hypersomnolence (CDHs) that significantly impact patients' quality of life (QoL). We investigated the recent medication use, comorbidities, and clinical burden among participants with CDHs from six European c…
Risk of depressive symptom burden across central disorders of hypersomnolence: A nationwide multicenter study.
Central disorders of hypersomnolence (CDH) significantly impair quality of life, yet the burden of depressive symptoms across their subtypes remains poorly understood. We aimed to examine the clinical profiles and risk factors for depression burden among patients with narcolepsy type 1 (NT1), narcol…